title: Anti-IL-6 receptor antibody causes less promotion of tuberculosis infection than anti-TNF-α antibody in mice.
abstract: Objective. Our aim was to investigate the effects of IL-6 blockade on the progression of Mycobacterium tuberculosis (TB) and compare them with those of TNF-α blockade in mice. Methods. Mice were intravenously infected with TB and injected with antibodies. Survival was monitored and histological and immunological studies were carried out. Results. All anti-IL-6R Ab-treated mice and 8 of 10 control mice survived until sacrificed 224 days after TB challenge, whereas anti-TNF-α Ab-treated mice all died between 120 and 181 days. Anti-IL-6R Ab-treated mice exhibited no significant differences in TB CFU in organs, including the lungs, and no deterioration in histopathology compared to control mice at 4 weeks. In contrast, anti-TNF-α Ab-treated mice exhibited increased TB CFU and greater progression of histopathological findings in organs than control mice. Spleen cells from anti-TNF-α Ab-treated mice had decreased antigen-specific response in IFN-γ release and proliferation assays. The results in anti-IL-6R Ab-treated mice suggest that spleen cell responses were decreased to a lesser degree. Similar results were obtained in IL-6 knockout (KO) mice, compared with TNF receptor 1 (TNFR1) KO and TNFR1/IL-6 double KO (DKO) mice. Conclusion. IL-6R blockade promotes the progression of TB infection in mice far less than TNF-α blockade.
authors: Clinical Research Center, National Hospital Organization Kinki-Chuo Chest Medical Center, Osaka 591-8555, Japan. okm@kch.hosp.go.jp
authors: Masaji
authors: M
authors: Okada
authors: Yoko
authors: Y
authors: Kita
authors: Noriko
authors: N
authors: Kanamaru
authors: Satomi
authors: S
authors: Hashimoto
authors: Yasushi
authors: Y
authors: Uchiyama
authors: Masahiko
authors: M
authors: Mihara
authors: Yoshikazu
authors: Y
authors: Inoue
authors: Yoshiyuki
authors: Y
authors: Ohsugi
authors: Tadamitsu
authors: T
authors: Kishimoto
authors: Mitsunori
authors: M
authors: Sakatani
references: Immunology. 2001 Jul;103(3):375-81
references: 11454067
references: J Immunol. 1988 Sep 1;141(5):1543-9
references: 3261754
references: Proc Natl Acad Sci U S A. 1993 Dec 15;90(24):11924-8
references: 8265649
references: J Rheumatol Suppl. 2005 Mar;74:35-9
references: 15742463
references: J Immunol. 1997 Oct 1;159(7):3595-602
references: 9317159
references: Proc Natl Acad Sci U S A. 1992 Oct 15;89(20):9784-8
references: 1409699
references: Immunology. 1994 Jul;82(3):361-4
references: 7959868
references: J Leukoc Biol. 2006 Jan;79(1):71-9
references: 16275895
references: J Immunol. 2006 Feb 15;176(4):2496-504
references: 16456010
references: Int Immunol. 2003 Aug;15(8):915-25
references: 12882829
references: J Clin Invest. 2004 Feb;113(3):401-13
references: 14755337
references: Infect Immun. 1997 Nov;65(11):4843-9
references: 9353074
references: J Exp Med. 1996 Apr 1;183(4):1345-55
references: 8666893
references: Expert Opin Biol Ther. 2008 May;8(5):669-81
references: 18407769
references: Vaccine. 2006 Feb 20;24(8):1191-204
references: 16216394
references: N Engl J Med. 2000 Nov 30;343(22):1586-93
references: 11096165
references: Infect Immun. 1990 Jan;58(1):269-71
references: 2104600
references: J Immunol. 2006 Aug 1;177(3):1416-20
references: 16849446
references: Cell. 1989 Mar 10;56(5):731-40
references: 2647299
references: Immunity. 1995 Jun;2(6):561-72
references: 7540941
references: Lancet. 2008 Mar 22;371(9617):987-97
references: 18358926
references: Infect Immun. 2005 Sep;73(9):5782-8
references: 16113296
references: Nature. 1994 Mar 24;368(6469):339-42
references: 8127368
references: Cancer Res. 1997 Apr 1;57(7):1335-43
references: 9102222
references: Cytokine. 2002 Dec 21;20(6):304-11
references: 12633573
references: J Immunol. 2001 Dec 15;167(12):6991-7000
references: 11739519
references: Clin Exp Immunol. 1998 Jun;112(3):397-402
references: 9649207
references: Rheumatol Int. 2011 Nov;31(11):1445-9
references: 20473503
references: Nat Med. 1996 Apr;2(4):430-6
references: 8597953
references: J Exp Med. 1993 Dec 1;178(6):2249-54
references: 7504064
references: Infect Immun. 2000 Jun;68(6):3322-6
references: 10816480
references: Annu Rev Immunol. 2001;19:93-129
references: 11244032
references: Eur J Immunol. 1997 Dec;27(12):3182-90
references: 9464804
references: Infect Immun. 1995 Jun;63(6):2262-8
references: 7768607
references: J Rheumatol. 2004 Jun;31(6):1132-8
references: 15170926
references: N Engl J Med. 2001 Oct 11;345(15):1098-104
references: 11596589
references: Infect Immun. 2004 Apr;72(4):2014-21
references: 15039321
references: Ann Rheum Dis. 2007 Sep;66(9):1162-7
references: 17485422
references: J Immunol. 1989 Jun 1;142(11):3884-93
references: 2469726
references: Lancet. 1999 Dec 4;354(9194):1932-9
references: 10622295
references: J Rheumatol. 2003 Jan;30(1):22-7
references: 12508385
references: Arthritis Rheum. 2003 Aug;48(8):2122-7
references: 12905464
references: J Immunol. 2003 Sep 15;171(6):3110-8
references: 12960337
references: J Immunol. 2006 Nov 15;177(10):7086-93
references: 17082625
references: Vaccine. 2005 Mar 18;23(17-18):2132-5
references: 15755583
references: N Engl J Med. 2000 Nov 30;343(22):1594-602
references: 11096166